Privately-held biopharma Intarcia Therapeutics revealed today that the FDA rejected its exenatide implant, ITCA 650, designed to treat Type II diabetes.
The company said that it doesn’t think it will need to conduct new pivotal trials in order to address the concerns brought about by the FDA’s complete response letter.
Get the full story at our sister site, Drug Delivery Business News.
The post FDA deals setback to Intarcia for diabetes implant appeared first on MassDevice.
from MassDevice http://ift.tt/2xOp1XG
Cap comentari:
Publica un comentari a l'entrada